A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Saysnews2024-04-04T12:18:29+00:00April 4th, 2024|The New York Times|
A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Marketnews2024-03-08T15:06:16+00:00March 8th, 2024|The New York Times|
A Rejected A.L.S. Drug Made Me Rethink the Role of Hope in Medicinenews2023-12-25T14:00:10+00:00December 25th, 2023|The New York Times|
FDA Approves Biogen’s Drug for Rare Form of ALSnews2023-04-25T17:53:59+00:00April 25th, 2023|The New York Times|
Price of New A.L.S. Treatment Will Be $158,000 Per Year, Maker Saysnews2022-09-30T20:16:18+00:00September 30th, 2022|The New York Times|
FDA Approves ALS Treatment Despite Questions About Effectivenessnews2022-09-29T21:14:36+00:00September 29th, 2022|The New York Times|
New Experimental Therapy for A.L.S. Approved in Canadanews2022-06-14T00:10:45+00:00June 14th, 2022|The New York Times|
New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Findsnews2022-03-30T22:45:15+00:00March 30th, 2022|The New York Times|
